MD Anderson Cancer Center Researchers Publish AML Preclinical Study on Bisantrene Drug Combinations

On May 10, 2021 Race Oncology Limited ("Race") reported a team of researchers, led by Professor Borje Andersson and Associate Professor Ben Valdez of the MD Anderson Cancer Center (Texas, USA), have identified a number of clinically translatable drug combinations that showed synergy with Bisantrene when tested in Acute Myeloid Leukaemia (AML) cells (Press release, Race Oncology, MAY 10, 2021, View Source [SID1234580138]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This study1, sponsored by Race, has been published in the Journal of Clinical & Experimental Oncology and is entitled "Synergism of the Anthracene-Derivative Anti-Cancer Agent Bisantrene with Nucleoside Analogs and A Bcl-2 Inhibitor in Acute Myeloid Leukemia Cells".

The MD Anderson team identified that Bisantrene, when used in combination with the standard-of-care AML drugs cytarabine, cladribine, fludarabine, clofarabine and/or ABT199 (Venetoclax) showed enhanced activation of apoptosis (cell killing) in AML cells. Combinations of three or more of these drugs with Bisantrene showed additional synergism and effective cell killing at drug concentrations far below that observed when the drugs were used on their own.

This work provides the preclinical data to support our upcoming Phase II relapsed / refractory AML trial at the Chaim Sheba Medical Center, where patients will be treated with Bisantrene in combination with the nucleoside analogs, clofarabine and fludarabine. This trial is scheduled to begin in Q2 CY2021. We are extremely excited about being able to quickly translate this work from the lab into the clinic, where it has the potential to help AML patients in need.